I. COMMENCED TRADING IN NOVEMBER

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price (M)

Shares Out

Lead, Other Underwriters#

Gross ($M)

Net ($M)

INITIAL OFFERINGS

Genomics One Corp.1 (Canada; MSE:GNX)

10/19

11/24

3U (US$0.85)

C$1.25 (US$2.56)

ND

PGS

C$3.75 (US$2.18)

C$3.2 (US$XX)

Oncolytics Biotech Inc.2 (Canada; ASE:ONC)

9/20

11/8

4S

C$0.85 (US$0.58)

ND

CCC

C$3.4 (US$2.3)

C$3 (US$2.04)

Symyx Technologies Inc.3 (SMMX)

9/21

11/17

5.5S

$14

27.7

CSFBC, DLJ, IA, SC

$77

$54.8

FOLLOW-ON OFFERINGS

Advanced Tissue Sciences Inc.4 (ATIS)

7/12

11/10

3.7U

$4

ND

Shares directly offered

$15

$14.25E

Alexion Pharmaceuticals Inc.5 (ALXN)

10/20

11/30

3S

$14

11.2

USBPJ, HQ

$47.8

$45.41E

BioCryst Pharmaceuticals Inc.6 (BCRX)

9/23

11/3

2S

$25.25

SSB, HQ, RJA

$50.5

$47.97E

Ilex Oncology Inc.7 (ILXO)

9/24

11/23

4.6S

$14

21.4

CIBC, PVHG, USBPJ

$64.4

$55.3

ImClone Systems Inc.8 (IMCL)

9/22

11/19

3.1S

$32

28.4

MSDW, ML, PVHG, WDR

$101.2

$94.3

Inex Pharmaceuticals Corp. (TSE:IEX)

10/18

11/23

4.5S

C$3.75 (US$2.55)

ND

NB, RBC, YS

C$17 (US$11.6)

C$16.15E (US$11.02E)

Progenics Pharmaceuticals Inc.9 (PGNX)

10/13

11/19

2S

$19

11.6

CIBC, RS, PVH, GKMC, PZC

$38

$35.2

Vion Pharmaceuticals Inc.10 (VION)

7/27

11/3

2.5

$5

18.2

BMC

$12.5

$11.15

Notes:

# See Underwriters' Key on page 7.

1 Genomics One Corp.'s prospectus leaves blank the number of shares outstanding.

2 Oncolytics Biotech Inc.'s prospectus leaves blank the number of shares outstanding.

3 The registered amount of 5.5M shares includes 0.8M shares to cover the overallotment option granted by Symyx to the underwriters

4 Advanced Tissue Sciences Inc.'s prospectus leaves blank the number of shares outstanding.

5 The registered amount of 2.5M shares does not include 0.4M shares to cover the overallotment option granted by Alexion to the underwriters. The underwriters exercised their overallotment option on Nov. 30 on 0.4M shares at $14 per share, increasing gross proceeds from $42M to $47.8M

6 The registered amount of 2.3M shares includes 0.3M shares to cover the overallotment option granted by BioCryst to the underwriters. Biocryst's registration statement leaves blank the number of shares outstanding.

7 The registered amount of 4.6M shares includes 0.6M shares to cover the overallotment option granted by Ilex to the underwriters, which was exercised on Nov. 30.

8 The stated number of 3.1M shares includes 0.4M shares to cover the overallotment option granted by ImClone to the underwriters, which was exercised on Nov. 30.

9 The registered amount of 2.3M shares includes 0.3M shares to cover the overallotment option granted by Progenics to the underwriters.

10 Vion's underwriters exercised their overallotment option on 0.3M shares at $5 per share on Nov. 3, increasing gross proceeds from $11M on Oct. 26 to $12.5M.

Company (Symbol)

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other UWs

Value (M)

INITIAL OFFERINGS

Antigenics LLC1

11/30

ND

ND

ND

USBPJ, RS

$46

Maxygen Inc.2

11/20

5S

$11-$13

ND

GS, RS, IA

­

Sequenom Inc.3

11/24

ND

ND

ND

WDR, RS, SGC

­

Tularik Inc.4

10/15

6.25S

ND

41.4

LBI, HQ, JPM, WDR

­

FOLLOW-ON OFFERINGS

There were no follow-on offerings filed in November.

Notes:

1 Antigenics' prospectus leaves blank the number of shares offered, the share price and the number of shares outstanding.

2 Maxygen's prospectus leaves blank the number of shares outstanding.

3 Sequenom's prospectus leaves blank the number of shares offered, the share price and the number of shares outstanding.

4 Tularik's prospectus leaves blank the share price.

OTHER NOTES:

E 3D estimated; ND 3D not disclosed, reported and/or available; S 3D shares; U 3D units; W 3D warrants

"Date filed" indicates the date on which the company announced that it had filed a preliminary prospectus with the Securities and Exchange Commission for its offering. It is not necessarily the same date as that which is printed on the preliminary prospectus itself.

In completed offerings, the number of shares sold includes the overallotment (in full or in part) if that option has been exercised by the time this publication goes to press.

Shares outstanding refers to the number of shares outstanding after the public offering. In the case of those offerings that are still pending, it assumes that the number of shares sold in the offering will be equal to the number intended for sale as per the prospectus.

Unless otherwise indicated, the stock symbols listed are on the Nasdaq Market.

ASE 3D Alberta Stock Exchange, MSE 3D Montreal Stock Exchange, NYSE 3D New York Stock Exchange; TSE 3D Toronto Stock Exchange

Conversion rate of C$1 3D US$0.68